

## Alacris Theranostics – advancing personalized oncology

Alacris offers advanced solutions for precision oncology because every patient is unique and every tumor is different. Precision oncology harnesses cancer sequencing (NGS) to seek out clinically actionable mutations; however, approaches that are restricted to gene panels or whole exome sequencing access only a limited fraction of the clinically-relevant molecular information. In many cases, a more comprehensive tumor analysis is essential for effective treatment guidance.

The unique value of the Alacris solution is the combination of exome and transcriptome sequencing. An integrative approach is essential for capturing key therapy-relevant components, such as oncogenic pathways, drug resistance signals and tumor microenvironment components, including immune infiltration.

Our validated strategy unlocks the most important information, leveraging accuracy and sensitivity to detect druggable events and better inform clinicians. Integrative NGS offers multiple benefits at a competitive price, opening up novel therapeutic avenues and options for combination and immune therapies, whilst avoiding ineffective treatments.

## Comprehensive Molecular Tumor Analysis (CMTA) – for patient-tailored therapy choices

The CMTA translates our long-standing expertise in genome and transcriptome research into an innovative product for high-precision tumor diagnostics.

We deploy advanced, validated bioinformatics pipelines, integrating whole transcriptome (RNAseq), whole exome (WES) and shallow whole genome (shWGS) sequence data. Starting from a single biopsy, we extract comprehensive tumor information and translate into a simple annotated report that covers tumor-specific molecular data, key molecular alterations and therapeutic options.

### One simple report – all key features

- Mutations
- Tumor mutation burden
- Copy number variants
- Gene fusions
- Gene expression profiling
- Oncogenic splice variants
- Key pathway signatures
- Drug resistance signatures
- Tumor microenvironment
- Immune infiltration

## Why adopt the CMTA approach?

- Holistic analysis unlocking key tumor alterations, oncogenic pathways and immune & stromal composition
- Enables personalized therapy for most tumors, including those of unknown origin
- Generates high-quality molecular data for clinical trials
- Flexible and customizable pipeline

### Clinical consultation

Background & benefits of CMTA

Metastatic cancers



Rare cancers

Cancers of unknown origin

### Data generation workflow

Whole exome and transcriptome



Blood



FFPE sample




Frozen biopsy




### NGS integrative analysis

Advanced bioinformatics pipelines



### Expert curated patient report

Key molecular findings & treatment options



From sample reception to final report